Treatment of infantile spasms with methysergide and alpha-methylparatyrosine.
Twenty-four newly diagnosed and previously untreated infantile spasm patients were treated for 3 weeks with either methysergide (12 patients) or alpha-methylparatyrosine (12 patients). Response to therapy was determined objectively with 24-h polygraphic/video monitoring techniques and was defined as cessation of spasms and disappearance of the hypsarrhythmic EEG pattern. Two (17%) of the patients treated with alpha-methylparatyrosine responded to therapy, and one (8%) of the methysergide-treated group showed a response.
Hrachovy
R A
RA
Department of Neurology, Baylor College of Medicine, Houston, Texas 77030.
Frost
J D
JD
Glaze
D G
DG
Rose
D
D
D000324:Adrenocorticotropic Hormone / Q000627:therapeutic use; D001463:Barbiturates / Q000627:therapeutic use; D002657:Child Development; D004569:Electroencephalography; D006801:Humans; D007223:Infant; D008781:Methyltyrosines / Q000008:administration & dosage / Q000627:therapeutic use*; D008784:Methysergide / Q000008:administration & dosage / Q000627:therapeutic use*; D010672:Phenytoin / Q000627:therapeutic use; D011897:Random Allocation; D012008:Recurrence; D013036:Spasms, Infantile / Q000188:drug therapy* / Q000503:physiopathology; D014446:Tyrosine 3-Monooxygenase / Q000037:antagonists & inhibitors*; D019805:alpha-Methyltyrosine
D001463:Barbiturates; D008781:Methyltyrosines; D010672:Phenytoin; D019805:alpha-Methyltyrosine; D000324:Adrenocorticotropic Hormone; D014446:Tyrosine 3-Monooxygenase; D008784:Methysergide